BECN1 and metabolic dysfunction-associated steatotic liver disease: BBM mitigates liver lipid metabolism disorders by modulating the SIRT1/LKB1/AMPK pathway, regulating the expression of autophagy markers LC3a/b, Beclin 1, and p62, and inducing autophagy to decelerate the progression of NAFLD.